Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
NasdaqGS - Nasdaq Real Time Price USD

Moderna, Inc. (MRNA)

Compare
31.12
-1.00
(-3.11%)
At close: March 28 at 4:00:01 PM EDT
31.20
+0.08
+(0.26%)
After hours: March 28 at 7:59:52 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
3,199,000
3,199,000
6,754,000
18,875,000
17,736,000
Cost of Revenue
1,464,000
1,464,000
4,693,000
5,416,000
2,617,000
Gross Profit
1,735,000
1,735,000
2,061,000
13,459,000
15,119,000
Operating Expense
5,680,000
5,680,000
6,300,000
4,039,000
1,823,000
Operating Income
-3,945,000
-3,945,000
-4,239,000
9,420,000
13,296,000
Net Non Operating Interest Income Expense
401,000
401,000
383,000
200,000
18,000
Other Income Expense
-63,000
-63,000
-86,000
-45,000
-29,000
Pretax Income
-3,607,000
-3,607,000
-3,942,000
9,575,000
13,285,000
Tax Provision
-46,000
-46,000
772,000
1,213,000
1,083,000
Net Income Common Stockholders
-3,561,000
-3,561,000
-4,714,000
8,362,000
12,202,000
Diluted NI Available to Com Stockholders
-3,561,000
-3,561,000
-4,714,000
8,362,000
12,202,000
Basic EPS
-9.28
-9.28
-12.33
21.26
30.31
Diluted EPS
-9.28
-9.28
-12.33
20.12
28.29
Basic Average Shares
384,000
384,000
382,000
394,000
403,000
Diluted Average Shares
384,000
384,000
382,000
416,000
431,000
Total Operating Income as Reported
-3,945,000
-3,945,000
-4,239,000
9,420,000
13,296,000
Total Expenses
7,144,000
7,144,000
10,993,000
9,455,000
4,440,000
Net Income from Continuing & Discontinued Operation
-3,561,000
-3,561,000
-4,714,000
8,362,000
12,202,000
Normalized Income
-3,505,728
-3,505,728
-4,657,120
8,362,000
12,202,000
Interest Income
425,000
425,000
421,000
200,000
18,000
Interest Expense
24,000
24,000
38,000
29,000
18,000
Net Interest Income
401,000
401,000
383,000
200,000
18,000
EBIT
-3,583,000
-3,583,000
-3,904,000
9,420,000
13,296,000
EBITDA
-3,394,000
-3,394,000
-3,283,000
9,768,000
13,528,000
Reconciled Cost of Revenue
1,464,000
1,464,000
4,693,000
5,416,000
2,617,000
Reconciled Depreciation
189,000
189,000
621,000
348,000
232,000
Net Income from Continuing Operation Net Minority Interest
-3,561,000
-3,561,000
-4,714,000
8,362,000
12,202,000
Total Unusual Items Excluding Goodwill
-56,000
-56,000
-72,000
-20,000
1,000
Total Unusual Items
-56,000
-56,000
-72,000
-20,000
1,000
Normalized EBITDA
-3,338,000
-3,338,000
-3,211,000
9,768,000
13,528,000
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-728
-728
-15,120
--
--
12/31/2021 - 12/7/2018

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

NVAX Novavax, Inc.
7.00
-3.58%
 
BNTX BioNTech SE
94.95
-0.47%
 
CRSP CRISPR Therapeutics AG
36.99
-2.76%
 
VKTX Viking Therapeutics, Inc.
25.65
-1.84%
 
SAVA Cassava Sciences, Inc.
1.6500
-2.94%
 
REGN Regeneron Pharmaceuticals, Inc.
637.36
+0.24%
 
TNXP Tonix Pharmaceuticals Holding Corp.
20.17
-24.37%
 
VRTX Vertex Pharmaceuticals Incorporated
492.69
-1.96%
 
SLNO Soleno Therapeutics, Inc.
71.99
+6.83%
 
RXRX Recursion Pharmaceuticals, Inc.
5.81
-2.68%